Because HER2‐targeted agents are an effective therapeutic approach for patients with overexpressed HER2 advanced/metastatic breast cancer,2, 3, 4, 5, 6, 7 HER2 levels should be assessed in all breast cancers. This evidence concerns the gene ERBB2 and breast carcinoma.